Splenic marginal zone lymphoma, iliac vein thrombosis, and monoclonal immunoglobulin Mκ antiphospholipid antibody with Annexin A5 interaction [16]

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1994-1996

  Martin, S Eric ^a,b,c   Abel, Robert F ^c  

^a HELEN F GRAHAM CANCER CENTER   (United States)

^b Christiana Care ^*  (United States)

^c Laboratory Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M KAPPA; LIPOCORTIN 5; PARAPROTEIN; PHOSPHOLIPID ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL RADIOGRAPHY; AGED; B CELL LYMPHOMA; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; ILIAC VEIN; LABORATORY TEST; LETTER; LEUKOPENIA; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; THROMBOCYTOPENIA; VEIN THROMBOSIS;

AGED; ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; ILIAC VEIN; IMMUNOGLOBULIN M; LYMPHOMA, B-CELL; SPLENIC NEOPLASMS; VENOUS THROMBOSIS;

EID: 33750488164     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600731972     Document Type: Letter

References (8)

1. Isaacson, P and Piris, M and Catovski, D and Swerd, Low and Montserrat, E and Berger, F and (2001) Splenic marginal zone lymphoma. In Tumors of Haematopoietic and Lymphoid tissues. WHO Classification of Tumors. (pp. 135-137). Lyon: IARC Press.
2. Murakami, H and Irisawa, H and Saitoh, T and Matsushima, T and Tamura, J and Sawamura, M and (1997) Immunological abnormalities in splenic marginal zone cell lymphoma Am J Hematol, 56, pp. 173-178.
3. Rand, J. (2002) Molecular pathogenesis of the antiphospholipid syndrome Circ Res, 90, pp. 29-37.
4. Rand, J and Wu, X and Lapinski, R and van Heerde, W and Reutelingsperger, C and Chen, P and (2004) Detection of antibody-mediated reduction of annexinA5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome Blood, 104, pp. 2783-2790.
5. Lieby, P and Poindron, V and Roussi, S and Klein, C and Knapp, A and Garaud, J and (2004) Pathogenic antiphospholipid antibody: An antigen-selected needle in a haystack Blood, 104, pp. 1711-1715.
6. Bennett, M and Sharma, K and Yegena, S and Gavish, I and Dave, H and Schechter, G. (2005) Rituximab monotherapy for splenic marginal zone lymphoma Haematologica, 90, pp. 856-858.
7. Treon, S and Branagan, A and Hunter, Z and Santos, D and Tournhilac, O and Anderson, K. (2004) Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia Ann Oncol, 15, pp. 1481-1483.
8. Gordan, L and Grow, W and Pusateri, A and Douglas, V and Mendenhall, N and Lynch, J. (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders J Clin Oncol, 23, pp. 1096-1102.